The use of two virus-neutralising antibodies casirivimab and imdevimab was found to reduce the risk and burden of COVID-19 infection, according to results from the phase III REGN-COV 2069 trial.
The trial which was conducted by Roche and Regeneron Pharmaceuticals evaluated a cocktail of two monoclonal antibodies casirivimab and imdevimab, to block infectivity of SARS-CoV-2 virus. The subcutaneous administration of the antibodies was found to alleviate the risk of symptomatic infections by 81% in those who were not infected when they entered the trial.
Additionally, those who received casirivimab and imdevimab and who still experienced a symptomatic infection resolved their symptoms on average within one week. This is in comparison to three weeks treatment with placebo, announced Roche.
The study included 1,505 people who were not infected with SARS-CoV-2 at baseline and received either one dose of casirivimab with imdevimab (1,200mg) or placebo, via subcutaneous injections.
The study also evaluated the antibody cocktail in a cohort of 204 recently infected asymptomatic patients. They were randomised to receive either one dose of casirivimab and imdevimab (1,200mg subcutaneous administration) or placebo.
Casirivimab and imdevimab reduced the overall risk of progressing to symptomatic COVID-19 by 31% in this cohort.
“The results confirm the potential dual value of casirivimab and imdevimab to reduce household COVID-19 infections and to decrease the disease burden in those who do become infected when given as a subcutaneous option,” said Levi Garraway, Roche chief medical officer and Global Product Development Head.
“Although vaccinations are increasing globally, there remains a critical unmet need worldwide to prevent infections and provide immediate protection from COVID-19 between close contacts.”
The company plans to continue testing the antibody cocktail in clinical trials in multiple settings for COVID-19.